Loading clinical trials...

COMPLETEDPHASE1

Vorinostat and Palliative Radiotherapy

Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.

NCT00455351•Oslo University Hospital

View on ClinicalTrials.gov

Summary

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pelvic malignancy
•Palliative radiation treatment planed
•ECOG \<3
•Age\>18 years

Exclusion Criteria

•Previous pelvic radiotherapy
•Uncontrolled diarrhea
•Insulin-dependent diabetes mellitus
•BMI\<18.5

Locations (1)

The Norwegian Radium Hospital

Oslo, Norway

Key Dates

Start Date

February 1, 2007

Primary Completion Date

March 1, 2009

Completion Date

August 1, 2009

Last Updated

May 8, 2023

Enrollment

ACTUAL participants

Conditions

Pelvic CancerRadiotherapy

Interventions

Vorinostat

DRUG

Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

NCT06719440

GlioblastomaRadiotherapy Side Effect

View study

RECRUITINGPHASE2

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

NCT07325721

Prostate CancerProstate Cancer Patients Treated by Radiotherapy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Vorinostat and Palliative Radiotherapy

Inclusion Criteria

Exclusion Criteria

Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

Hippotherapy Teenager-pediatric Radiotherapy

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）

Perioperative Complications After Neoadjuvant Radiotherapy for Colorectal Cancer